Drugs.com Clinical Trial ResultsOriginal article
Novo Nordisk Provides Update on the ZEUS Phase 3 Trial of Ziltivekimab in People with ASCVD, CKD and Inflammation
Phase 3ziltivekimabPositive
AI Analysis
Summary
Novo Nordisk announced headline results from the ZEUS Phase 3 trial of ziltivekimab in patients with ASCVD, CKD, and inflammation, demonstrating target engagement and IL-6 pathway inhibition.
Clinical Trial Data
Phase
Phase 3
Outcome Details
Demonstrated target engagement and inhibition of IL-6 pathway
Importance:6/10
Sentiment:
0.50
cardiovascular outcomesinflammationIL-6 pathwayPhase 3ZEUS trial
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on July 31, 2026 8:08 PM